CY1122454T1 - Στερεες δοσολογικες μορφες palbociclib - Google Patents

Στερεες δοσολογικες μορφες palbociclib

Info

Publication number
CY1122454T1
CY1122454T1 CY20201100002T CY201100002T CY1122454T1 CY 1122454 T1 CY1122454 T1 CY 1122454T1 CY 20201100002 T CY20201100002 T CY 20201100002T CY 201100002 T CY201100002 T CY 201100002T CY 1122454 T1 CY1122454 T1 CY 1122454T1
Authority
CY
Cyprus
Prior art keywords
dosage forms
solid dosage
palbociclib
palbociclib solid
water
Prior art date
Application number
CY20201100002T
Other languages
English (en)
Inventor
Fady Makram Louiz IBRAHIM
Matthew Patrick MULLARNEY
Ravi Mysore Shanker
Barbara Rodriguez SPONG
Jian Wang
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56092955&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122454(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of CY1122454T1 publication Critical patent/CY1122454T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Η παρούσα εφεύρεση αναφέρεται σε στερεές δοσολογικές μορφές palbociclib που περιλαμβάνουν ένα υδατοδιαλυτό οξύ. Οι περιγραφόμενες στο παρόν δοσολογικές μορφές έχουν επιθυμητά φαρμακοκινητικά χαρακτηριστικά.
CY20201100002T 2015-06-04 2020-01-03 Στερεες δοσολογικες μορφες palbociclib CY1122454T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562171177P 2015-06-04 2015-06-04
US201662332973P 2016-05-06 2016-05-06
PCT/IB2016/053040 WO2016193860A1 (en) 2015-06-04 2016-05-24 Solid dosage forms of palbociclib

Publications (1)

Publication Number Publication Date
CY1122454T1 true CY1122454T1 (el) 2021-01-27

Family

ID=56092955

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100002T CY1122454T1 (el) 2015-06-04 2020-01-03 Στερεες δοσολογικες μορφες palbociclib

Country Status (31)

Country Link
US (2) US11065250B2 (el)
EP (2) EP3302565B1 (el)
JP (3) JP2017002034A (el)
KR (2) KR102369405B1 (el)
CN (2) CN113616606A (el)
AU (2) AU2016272881C1 (el)
BR (1) BR112017025398A2 (el)
CA (1) CA2931892A1 (el)
CL (1) CL2017003089A1 (el)
CO (1) CO2017012362A2 (el)
CR (1) CR20170540A (el)
CY (1) CY1122454T1 (el)
DK (1) DK3302565T3 (el)
DO (1) DOP2017000280A (el)
ES (1) ES2764459T3 (el)
HK (1) HK1250570A1 (el)
HR (1) HRP20192065T1 (el)
HU (1) HUE047477T2 (el)
IL (2) IL255632A (el)
LT (1) LT3302565T (el)
MX (2) MX2017015579A (el)
PE (1) PE20180395A1 (el)
PL (1) PL3302565T3 (el)
PT (1) PT3302565T (el)
RS (1) RS59672B1 (el)
RU (1) RU2686840C1 (el)
SA (1) SA517390473B1 (el)
SI (1) SI3302565T1 (el)
TW (2) TWI635863B (el)
WO (1) WO2016193860A1 (el)
ZA (1) ZA201707780B (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE048293T2 (hu) 2008-10-02 2020-07-28 Salix Pharmaceuticals Ltd Eljárások hepatikus enkefalopátia kezelésére
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
WO2017115315A1 (en) * 2015-12-30 2017-07-06 Dr. Reddy's Laboratories Limited Solid forms of palbociclib
CN105816437B (zh) * 2016-03-29 2018-08-03 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
US10449195B2 (en) * 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN108210454A (zh) * 2016-12-14 2018-06-29 深圳市华力康生物医药有限公司 一种帕布昔利布的口服乳剂及其制备方法
AU2018210141A1 (en) * 2017-01-20 2019-08-29 Constellation Pharmaceuticals, Inc. Solid dispersions of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
WO2018165404A1 (en) * 2017-03-08 2018-09-13 Cinrx Pharma, Llc Pharmaceutical formualtions of phloroglucinol and trimethylphloroglucinol
WO2018191950A1 (en) * 2017-04-21 2018-10-25 Alnova Pharmaceuticals, Ltd. Palbociclib compositions and methods thereof
AU2018275631A1 (en) * 2017-05-31 2019-10-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
CN106970177B (zh) * 2017-06-06 2018-05-15 北京元延医药科技股份有限公司 帕博西尼中间体及其杂质的分析检测方法
WO2019013310A1 (en) 2017-07-10 2019-01-17 Takeda Pharmaceutical Company Limited PREPARATION COMPRISING VONOPRAZAN
US11529353B2 (en) 2017-07-28 2022-12-20 Synthon B.V. Pharmaceutical composition comprising Palbociclib
CN110997666A (zh) * 2017-09-19 2020-04-10 浙江华海药业股份有限公司 N-甲酰基帕博西尼及其制备方法和用途以及帕博西尼制剂及其质量控制方法
CA3080197C (en) * 2017-10-27 2023-12-19 Plexxikon Inc. Formulations of a compound modulating kinases
CN108014343A (zh) * 2017-12-21 2018-05-11 孟斯琴 一种治疗乳腺癌的药物组合物及其制备方法
CN108066303A (zh) * 2017-12-31 2018-05-25 湖南博隽生物医药有限公司 一种抗癌药物组合物及其制备方法
CA3092003A1 (en) 2018-02-27 2019-09-06 Pfizer Inc. Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
US11911383B2 (en) 2018-05-14 2024-02-27 Pfizer Inc. Oral solution formulation
CN108653222A (zh) * 2018-07-03 2018-10-16 威海贯标信息科技有限公司 一种帕博西尼片剂组合物
CN109575021B (zh) * 2019-01-22 2020-09-18 北京海美桐医药科技有限公司 一种哌柏西利的制备方法
US20220125777A1 (en) 2019-02-01 2022-04-28 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
AU2021299348A1 (en) * 2020-07-02 2023-02-02 Artham Therapeutics Inc. Oral pharmaceutical composition and method for producing same
CA3189632A1 (en) 2020-07-20 2022-01-27 Pfizer Inc. Combination therapy
CN114246872B (zh) * 2020-09-24 2024-02-06 南京济群医药科技股份有限公司 一种改善羟乙磺酸哌柏西利流动性的工艺方法及组合物
CN114306245A (zh) * 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
EP4302832A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing glucono delta lactone
EP4302755A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing an amino acid

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
BR9713552A (pt) 1996-11-27 2000-01-25 Pfizer Derivados de pirimidina bicìclicos condensados
ATE314370T1 (de) * 2002-01-22 2006-01-15 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
JP4053073B2 (ja) 2003-07-11 2008-02-27 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 選択的ｃｄｋ４阻害剤のイセチオン酸塩
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
JP2009504796A (ja) * 2005-08-22 2009-02-05 ノバルティス アクチエンゲゼルシャフト ｐＨ依存性薬剤化合物、ｐＨ調整剤および遅延剤を含む医薬組成物
GB0517204D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
NZ569984A (en) 2006-01-27 2011-06-30 Eurand Inc Drug delivery systems comprising weakly basic drugs and organic acids
BRPI0716880A2 (pt) 2006-09-08 2013-10-15 Pfizer Prod Inc Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
WO2008032162A1 (en) 2006-09-15 2008-03-20 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
AU2010302419B2 (en) * 2009-09-30 2014-07-31 Merck Sharp & Dohme (Uk) Limited Formulations for c-Met kinase inhibitors
US8557995B2 (en) * 2010-06-09 2013-10-15 Abbvie Inc. Solid dispersions containing kinase inhibitors
CN103945831A (zh) 2011-11-23 2014-07-23 诺华股份有限公司 医药制剂
US20130183384A1 (en) 2011-12-22 2013-07-18 Boehringer Ingelheim International Gmbh Immediate release multi unit pellet system
KR101858913B1 (ko) 2013-02-21 2018-05-16 화이자 인코포레이티드 고체 형태의 선택적인 cdk4/6 억제제
PT3033086T (pt) * 2013-08-14 2021-12-15 Novartis Ag Terapia de combinação para o tratamento de cancro
CA2929181A1 (en) * 2013-11-13 2015-05-21 Novartis Ag Mtor inhibitors for enhancing the immune response
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
CN105816437B (zh) 2016-03-29 2018-08-03 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof

Also Published As

Publication number Publication date
AU2016272881A1 (en) 2017-12-07
MX2020003825A (es) 2020-08-06
US20180207100A1 (en) 2018-07-26
IL287437A (en) 2021-12-01
CN113616606A (zh) 2021-11-09
NZ737391A (en) 2023-11-24
CN107666914A (zh) 2018-02-06
JP2023112149A (ja) 2023-08-10
EP3302565B1 (en) 2019-11-06
TW201711687A (zh) 2017-04-01
EP3302565A1 (en) 2018-04-11
US11065250B2 (en) 2021-07-20
KR102068423B1 (ko) 2020-01-20
EP3636283A1 (en) 2020-04-15
TW201906611A (zh) 2019-02-16
SA517390473B1 (ar) 2022-12-11
PE20180395A1 (es) 2018-02-28
WO2016193860A1 (en) 2016-12-08
SI3302565T1 (sl) 2020-02-28
TWI635863B (zh) 2018-09-21
TWI763881B (zh) 2022-05-11
DOP2017000280A (es) 2018-01-15
RU2686840C1 (ru) 2019-05-06
RS59672B1 (sr) 2020-01-31
PT3302565T (pt) 2020-01-14
IL255632A (en) 2018-01-31
HUE047477T2 (hu) 2020-04-28
KR20200006633A (ko) 2020-01-20
ZA201707780B (en) 2020-05-27
CL2017003089A1 (es) 2018-05-11
ES2764459T3 (es) 2020-06-03
US20210315900A1 (en) 2021-10-14
PL3302565T3 (pl) 2020-06-01
CA2931892A1 (en) 2016-12-04
CR20170540A (es) 2018-02-02
CO2017012362A2 (es) 2018-03-28
LT3302565T (lt) 2019-12-27
JP2021167343A (ja) 2021-10-21
AU2019204689B2 (en) 2020-12-03
HRP20192065T1 (hr) 2020-02-21
KR102369405B1 (ko) 2022-03-02
AU2016272881B2 (en) 2019-04-11
DK3302565T3 (da) 2020-01-02
KR20180015232A (ko) 2018-02-12
AU2019204689A1 (en) 2019-07-18
JP2017002034A (ja) 2017-01-05
AU2016272881C1 (en) 2019-10-03
HK1250570A1 (zh) 2018-12-28
BR112017025398A2 (pt) 2018-08-07
MX2017015579A (es) 2018-03-27

Similar Documents

Publication Publication Date Title
CY1122454T1 (el) Στερεες δοσολογικες μορφες palbociclib
CY1123358T1 (el) Υδατικο φαρμακευτικο σκευασμα που περιεχει αντισωμα αντι-pd-1 αβελουμαμπη
CL2016002455A1 (es) Anticuerpos multiespecíficos.
EA201891211A1 (ru) Ингибиторы cxcr2
EA202092435A3 (ru) Моноклональные антитела против bcma
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
EA201992177A1 (ru) Композиции на основе нирапариба
CY1124587T1 (el) Μεθοδος για την παρασκευη toy brivaracetam
TR201909606T4 (tr) Pi̇razollari hazirlamak i̇çi̇n i̇şlem
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
EA201792021A1 (ru) Ингибитор jak
CY1124406T1 (el) Αζασετρονη για χρηση στη θεραπεια της απωλειας ακοης
EA201791684A1 (ru) Селективные ингибиторы bace1
EA201790184A1 (ru) Пестицидные композиции
EA201692548A1 (ru) Минеральные аминокислотные комплексы активных веществ
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
CY1122578T1 (el) Φαρμακευτικο σκευασμα το οποιο περιλαμβανει αντισωμα
CY1117490T1 (el) Μεθοδος παραγωγης της μεδετομιδινης
EA201890322A1 (ru) Новый вид тобамовируса
EA201692368A1 (ru) Производные, полученные из гиалуроновой кислоты и карнозина
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
CY1118945T1 (el) Μεθοδος και ενδιαμεσα για την παρασκευη πρεγκαμπαλινης
FR3058143B1 (fr) Nanocorps anti-tau